Telpegfilgrastim - Xiamen Amoytop Biotech
Alternative Names: Pegneugen; Telpegfilgrastim injection - Xiamen Amoytop Biotech; Y-shaped branched pegylated filgrastim - Xiamen Amoytop Biotech; YPEG-filgrastim - Xiamen Amoytop Biotech; YPEG-rhG-CSF - Xiamen Amoytop BiotechLatest Information Update: 28 Aug 2023
At a glance
- Originator Xiamen Amoytop Biotech
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Chemotherapy induced febrile neutropenia
Most Recent Events
- 01 Jul 2023 Xiamen Amoytop Biotech has patent protection for Telpegfilgrastim in an undisclosed location
- 01 Jul 2023 Efficacy data from a phase III trial in Chemotherapy induced febrile neutropenia released by Xiamen Amoytop Biotech
- 01 Jul 2023 Pooled adverse events data from clinical trials in Chemotherapy induced febrile neutropenia released by Xiamen Amoytop Biotech